(CSE: MMET) (FSE: 8NQ) (OTCQX: MMETF) (“Miata” or the “Company”) is pleased to announce that it has completed the first four ...

Immunic presents additional phase 2 CALLIPER trial data for vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026: New York Friday, February 6, 2026, 16:0 ...